Evidence map›Paper›PMID 42050186›Full record

ArticleArchives of toxicology2026

The role of cytotoxicity in the process of carcinogenesis.

Michael Schwarz, Bernd Epe, Laura E Wohak, Carola Voss, Andrea Hartwig

Abstract readLetter
In one paragraph

Article in Archives of toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Michael SchwarzDepartment for Experimental and Clinical Pharmacology and Pharmacogenomics, Eberhard Karls University, Wilhelmstr. 56, 72074, Tübingen, Germany. michael.schwarz@uni-tuebingen.de.ORCID 0009-0000-2193-7968
Bernd EpeInstitute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University Mainz, Staudinger Weg 5, 55128, Mainz, Germany.
Laura E WohakInstitute of Applied Biosciences (IAB), Food Chemistry and Toxicology, Karlsruhe Institute of Technology (KIT), Adenauerring 20a, 76131, Karlsruhe, Germany.
Carola VossClinic for Cardiac, Thoracic, Transplantation and Vascular Surgery, Leibniz Research Laboratories for Biotechnology and Artificial Organs (LEBAO), Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), German Center for Lung Research (DZL), Hannover Medical School, Carl Neuberg-Str. 1, 30625, Hannover, Germany.
Andrea HartwigInstitute of Applied Biosciences (IAB), Food Chemistry and Toxicology, Karlsruhe Institute of Technology (KIT), Adenauerring 20a, 76131, Karlsruhe, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Enhanced cancer prevalence findings restricted to high, cytotoxic dose levels in long-term animal cancer studies are generally assumed to be a consequence of-indirect or secondary-mutational effects, e.g. DNA damage mediated by generation of reactive oxygen species (ROS) or replication errors occurring during regenerative cell proliferation. An alternative explanation is provided by recent findings suggesting that cell lysis caused by cytotoxic doses of non-genotoxic agents may give rise to tumor promotion by selective growth stimulation of pre-existing (already mutated) dormant tumor precursor cells. This growth stimulation is assumed to be mediated by damage-associated molecular pattern (DAMP) signaling ("sterile inflammation"). Here, we discuss the differing views on cancer findings observed only at high cytotoxic doses in particular with respect to the implications for the risk assessment of the agents.

Indexed as

CarcinogenesisCell Transformation, NeoplasticNeoplasmsAnimalsCell ProliferationDNA DamageHumansReactive Oxygen SpeciesRisk AssessmentSignal TransductionReactive Oxygen SpeciesCarcinogenesisCytotoxicityDAMPsROSTumor promotion

Identifiers

PMID42050186
PMCPMC13379468

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.